Press release
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche
"Systemic Lupus Erythematosus Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.
The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years.
*
Systemic Lupus Erythematosus companies working in the treatment market are Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others, are developing therapies for the Systemic Lupus Erythematosus treatment
*
Emerging Systemic Lupus Erythematosus therapies in the different phases of clinical trials are- Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.
*
In October 2024, The FDA has approved Cullinan Therapeutics' investigational new drug (IND) application for CLN-978, intended to treat systemic lupus erythematosus (SLE).
*
In September 2024, Cartesian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation to Descartes-08 for treating juvenile dermatomyositis (JDM).
*
In September 2024, Caribou Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designation to its CAR T-cell therapy CB-010 for the treatment of systemic lupus erythematosus (SLE)
*
In September 2024, UCB and Biogen announced positive outcomes from their Phase III PHOENYCS GO clinical trial, evaluating dapirolizumab pegol as a treatment for moderate-to-severe systemic lupus erythematosus.
*
In August 2024, Conduit Pharmaceuticals announced plans to conduct a Phase IIa clinical trial to assess AZD1656 for treating multiple autoimmune diseases, including systemic lupus erythematosus (SLE).
*
In July 2024, The first patient has been treated with Descartes-08 for systemic lupus erythematosus. This therapy was previously used in patients with myasthenia gravis, a chronic autoimmune disorder causing muscle weakness.
*
In February 2024, Idorsia Pharmaceuticals has established a significant global research and development partnership with Viatris to advance and commercialize two Phase III assets, selatogrel and cenerimod, worldwide.
Systemic Lupus Erythematosus Overview
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect various parts of the body. In this condition, the immune system mistakenly attacks healthy tissues and organs, leading to inflammation, pain, and damage to different systems within the body.
Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight [https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:
*
Mosunetuzumab: Roche
*
Itolizumab: Equillium/ Biocon Limited
*
KPG 818: Kangpu Biopharmaceuticals
*
BOS161721: Boston Pharmaceuticals S
*
NKTR-358: Nektar Therapeutics
*
ABBV-599: AbbVie
*
Daxdilimab (VIB7734): Horizon Therapeutics
*
SAR441344: Sanofi
*
BIIB059: Biogen
*
Obinutuzumab: Hoffman-La-Roche
Systemic Lupus Erythematosus Route of Administration
Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intra-articular
*
Intraocular
*
Intrathecal
*
Intravenous
*
Ophthalmic
*
Oral
*
Parenteral
*
Subcutaneous
*
Topical
*
Transdermal
Systemic Lupus Erythematosus Molecule Type
Systemic Lupus Erythematosus Products have been categorized under various Molecule types, such as
*
Oligonucleotide
*
Peptide
*
Small molecule
Systemic Lupus Erythematosus Pipeline Therapeutics Assessment
*
Systemic Lupus Erythematosus Assessment by Product Type
*
Systemic Lupus Erythematosus By Stage and Product Type
*
Systemic Lupus Erythematosus Assessment by Route of Administration
*
Systemic Lupus Erythematosus By Stage and Route of Administration
*
Systemic Lupus Erythematosus Assessment by Molecule Type
*
Systemic Lupus Erythematosus by Stage and Molecule Type
DelveInsight's Systemic Lupus Erythematosus Report covers around 60+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:
Key companies developing therapies for Systemic Lupus Erythematosus are - Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, F. Hoffmann-La Roche AG, Pfizer Limited, ImmuPharma PLC, Bristl Myers Squibb Company, AstraZeneca, Merck & Co., Inc., and others.
Systemic Lupus Erythematosus Pipeline Analysis:
The Systemic Lupus Erythematosus pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
*
Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Systemic Lupus Erythematosus Pipeline Market Drivers
*
Promising Therapeutic Approaches, increasing Awareness of the Disease, recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.
Systemic Lupus Erythematosus Pipeline Market Barriers
*
However, obstacles in Systemic Lupus Erythematosus Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.
Scope of Systemic Lupus Erythematosus Pipeline Drug Insight
*
Coverage: Global
*
Key Systemic Lupus Erythematosus Companies: Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others
*
Key Systemic Lupus Erythematosus Therapies: Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others
*
Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
*
Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers
Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Systemic Lupus Erythematosus Report Introduction
2. Systemic Lupus Erythematosus Executive Summary
3. Systemic Lupus Erythematosus Overview
4. Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment
5. Systemic Lupus Erythematosus Pipeline Therapeutics
6. Systemic Lupus Erythematosus Late Stage Products (Phase II/III)
7. Systemic Lupus Erythematosus Mid Stage Products (Phase II)
8. Systemic Lupus Erythematosus Early Stage Products (Phase I)
9. Systemic Lupus Erythematosus Preclinical Stage Products
10. Systemic Lupus Erythematosus Therapeutics Assessment
11. Systemic Lupus Erythematosus Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Systemic Lupus Erythematosus Key Companies
14. Systemic Lupus Erythematosus Key Products
15. Systemic Lupus Erythematosus Unmet Needs
16 . Systemic Lupus Erythematosus Market Drivers and Barriers
17. Systemic Lupus Erythematosus Future Perspectives and Conclusion
18. Systemic Lupus Erythematosus Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=systemic-lupus-erythematosus-pipeline-report-2024-clinical-trials-progress-and-therapeutic-advancements-sanofi-sa-eli-lilly-company-viatris-inc-novartis-ag-glaxosmithkline-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche here
News-ID: 3813160 • Views: …
More Releases from ABNewswire
Micro Delight Observes Growing Demand for Magnifying Lamps Across Thailand
Micro Delight, a long-established supplier of magnifying lamps [https://xn--22cd7dxajja0b4gtgh0a9c.com/] based in Bangkok, reports a continued rise in nationwide demand for professional magnification and lighting tools. This growth reflects the increasing need for precision and visual clarity in Thailand's manufacturing, laboratory, and craftsmanship sectors.
The company notes that more businesses are prioritizing equipment that supports detailed inspection work. Industries such as electronics assembly, jewelry production, gemstone grading, dental laboratories, repair centers, and…
Bridging Health and Digital: Vinay Raval Announces Launch of VB Wellcare and Val …
Vinay Raval, a dynamic Digital Marketing Consultant, announces a strategic expansion back into healthcare. After transitioning from a Pharmacist to a global SEO expert serving clients like El Corte Ingles and Engelbert Strauss, Raval is merging his two worlds. He is launching VB Wellcare to help pharma agencies digitize and Value Beyond, a premium nutraceutical brand for the US market. This venture combines his MPharm background with a decade of…
Appy Pie Agents Launches AI Gyms & Fitness Centers Voice Receptionist to Automat …
Appy Pie Agents has launched an AI Gyms & Fitness Centers Voice Receptionist to automate member calls, provide class and membership details, and support bookings.
NOIDA, Uttar Pradesh, India - December 09, 2025 - Appy Pie Agents, a leading no-code AI agent builder [https://www.appypieagents.ai/] platform, has announced the launch of its new AI Gyms & Fitness Centers Voice Receptionist, giving fitness clubs, gyms, yoga studios, training centers, and wellness facilities a…
Revolutionizing Minimally Invasive Surgery: How the EziSurg Laparoscopic Stapler …
In an age when minimally invasive procedures are becoming the norm, the demand for surgical instruments that combine efficiency, precision, and safety has never been higher. Enter the laparoscopic stapler from EziSurg Medical - a device that the company now highlights as a "specialized medical instrument" designed to deliver secure internal tissue stapling and cutting through small incisions.
A Core Tool for Modern Minimally Invasive Surgery
According to EziSurg, the laparoscopic stapler…
More Releases for Systemic
What Is Driving Global Systemic Aspergillosis And Systemic Candidiasis Market Gr …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Systemic Aspergillosis And Systemic Candidiasis Market Size Growth Forecast: What to Expect by 2025?
The market valuation for systemic aspergillosis and systemic candidiasis has experienced consistent upward momentum across recent years, projected to advance from a figure of $7.24 billion in 2024 to reach $7.57 billion by 2025, reflecting…
Transformative Trends Impacting the Systemic Aspergillosis And Systemic Candidia …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Systemic Aspergillosis And Systemic Candidiasis Market Size By 2025?
The growth trend of the systemic aspergillosis and systemic candidiasis market has been steadily ascending in the past few years. The market size will inflate from $7.24 billion in 2024 to $7.59 billion in 2025, indicating…
Systemic Aspergillosis And Systemic Candidasis Market Size by Type, Application, …
According to Market Research Intellect, the global Systemic Aspergillosis And Systemic Candidasis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The growing prevalence of invasive fungal infections, especially in immunocompromised persons, is propelling the global…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market - Industry Over …
The systemic aspergillosis and systemic candidiasis treatment market is gaining significant attention within the global healthcare and pharmaceutical industries due to the increasing incidence of life-threatening fungal infections among immunocompromised individuals. Both systemic aspergillosis and systemic candidiasis are opportunistic fungal infections, often affecting patients with weakened immune systems due to cancer therapy, organ transplantation, HIV/AIDS, or intensive care treatments.
The systemic aspergillosis and systemic candidiasis treatment market was valued at approximately…
Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
To get sample Copy of the report, along with…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market Insight & Futur …
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Systemic Aspergillosis and Systemic Candidiasis Treatment Market in the latest research report added by Big Market Research. The recent research report on the global Systemic Aspergillosis and Systemic Candidiasis Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end…
